Dana-farber-cancer Institute Inc.

Harvard College

The Brigham and Women's Hospital, Inc.

Novartis Ag

Emory University

Other

Children's Medical Center Corporation

Leland Stanford Junior University

University of Pennsylvania

Wyeth

Beth Israel Deaconess Medical Center, Inc.

USA As Represented by Secretary of the Navy

University of Michigan

University System of Maryland

Institut National De La Sante Et De La Recherche Medicale

Gordon James Freeman

Arlene Helen Sharpe

Lee M Nadler

Jennifer Marie Mataraza

Dale T Umetsu

Gary S Gray

Rafi Ahmed

Catherine Anne Sabatos-Peyton

Walter A Blattler

Gerhard Johann Frey

Hwai Wen Chang

Vassiliki A Boussiotis

Clive R Wood

Edward Alvin Greenfield

Rosemarie Dekruyff

Vijay K Kuchroo

Maximiliano Vasquez

Timothy David Jones

Francis J Carr

Thomas Huber

Daniel Hicklin

Barbara Brannetti

Fangmin Xu

Tiancen Hu

James Peter Gregson

Yanping Xiao

Thomas Pietzonka

John A Taraszka

Francescopaolo Borriello

Tatyana Chernova

Nelly Malenkovich

Rosemarie H DeKruyff

Alan S Harris

Laurie H Glimcher

Suzanne Ostrand-Rosenberg

Joachim L Schultze

E John Wherry

Jason L Gaglia

Hanspeter Waldner

John G Gribben

David M Dorfman

Daniel Barber

Laurent Monney

Paul David Rennert

Glenn Dranoff

Sivasubramanian Baskar

Loise M Francisco

Vikram R Juneja

Jennifer Brogdon

Harvey I Cantor

Reshma Singh

Boris Engels

Jennifer L Jones

Susan Knox

Roberto M Patarca

Divya Chaudhary

Cindy L Jellis

Arnold S Freedman

Jennifer Jones McIntire

Irene Chernova

Kathryn T Hall

Xia Bu

Nikolaos Patsoukis

Jessica Weaver

Laura Strauss

Carl H June

Gary J Nabel

Craig B Thompson

Armand Bensussan

Francis Joseph Carr

Jean Zhao

Laurence Boumsell

Scott J Rodig

Rama Rao Amara

Thomas M Roberts

F Stephen Hodi

Yvette Latchman

Peter T Sage

Sumone Chakravarti

Joel L Schwartz

Matthew Vanneman

Rosemarie H De Kruyff

Adam Bass

Xinqi Wu

Jingjing Li

Sivasubramanina Baskar

Masao Hashimoto

Janet Buhlman

Hyun T Jin

Didier Mandelbrot

Hyeryun Choe

Stephanie Jemielity

Johann Bergholz

Sanhong Yu

Sarah Derks

Jun Zhou

Sun J Lee

Scott B Lovitch

Catherine L Tan

Vijayakumar Velu

The present invention is based, in part, on the discovery of monoclonal and polyclonal antibodies that specifically bind to phosphorylated PD-1, as well as immunoglobulins, polypeptides, nucleic acids thereof, and methods of using such antibodies for diagnostic, prognostic, and therapeutic purposes.

Method of assessing the efficacy of a test agent for modulating programmed death 1 (PD-1) signaling by using anti-phosphotyrosinylated PD-1 monoclonal antibodies

Provided are compositions and methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.

Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy

The present invention relates to methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents.

Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents

The present invention is based, in part, on the discovery of monoclonal antibodies, and antigen-binding fragments thereof, that specifically bind to HHLA2, as well as immunoglobulins, polypeptides, nucleic acids thereof, and methods of using such antibodies for diagnostic, prognostic, and therapeutic purposes.

KIR3DL3 as an HHLA2 receptor, anti-HHLA2 antibodies, and uses thereof

Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.

Antibody molecules to PD-1 and uses thereof

The present invention relates to compositions and methods for identifying, assessing, preventing, and treating melanoma. A variety of PD-L1 isoform biomarkers are provided, wherein alterations in the copy number of one or more of the biomarkers and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers is associated with melanoma status.

Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms

Anti-phosphotyrosinylated programmed death 1 (PD-1) monoclonal antibodies, methods of making and methods of using thereof

The present invention relates to compositions and methods for the modulation RGMb-Neogenin-BMP signaling.

Agents that modulate RGMb-neogenin-BMP signaling and methods of use thereof

Provided are compositions for use in methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.

The present invention relates to compositions and methods for the immunomodulation mediated by the interaction of PD-L2 and RGMb.

Agents that modulate immune cell activation and methods of use thereof

The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and cancer.

Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway

The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infections diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.

Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor

The present invention is based, in part, on the identification of methods of modulating PD-1 expression and/or activity in regulatory T cells (Tregs) to thereby regulate effector immune responses in effector T cells (Teffs).

Regulatory T cell PD-1 modulation for regulating T cell effector immune responses

Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.

Method of detecting TIM-3 using antibody molecules to TIM-3

Growing community of inventors

Brookline, MA, United States of America

Gordon James Freeman